![]() | Only 14 pages are availabe for public view |
Abstract Hepatocellular carcinoma is considered the commonest primary hepatic cancer, the fifth most frequent cancer worldwide and the third cause of cancer related mortality. Hepatitis C virus is the etiological agent of hepatitis C which is an infectious disease affecting the liver. It has high tendency to cause chronic progressive hepatic damage and HCC. Toll-like receptors (TLRs) are evolutionarily conserved membranebound proteins. They are widely expressed on the surface of immune cells. Toll-like receptors have an imperative role in immunity, neurogenesis and developmental processes across the eukaryotic species. Toll-like receptors (TLRs) stand out as significant players in the pathogenesis of HCC. TLRs are capable of recognizing PAMPs/DAMPs and initiating related intracellular signaling pathways. In the human immune and non-immune cells, there are a total of 10 TLRs, which utilize different adaptor proteins. Toll-like receptor 4 (TLR4) can be stimulated by HCV nonstructural protein NS5A and thereby results in the secretion of IFNs and IL6 from hepatocyte and B cells. The activation of and TLR4 signaling in hepatocyte leads to upregulation of pro inflammatory cytokines and chemokines and recruitment of inflammatory cells to the liver. Toll-like receptor 4 (TLR4) gene polymorphism was identified to be a good prognostic predictor for the development of cirrhosis in HCV infected patients. Also, it was shown that TLR4 SNPs are associated with protection from liver fibrosis, possibly through conformational changes of the protein, thereby affecting its interaction with other proteins. This study aimed to determine the association between two single nucleotide polymorphisms (rs2149356, rs1927914) of TLR4 gene and HCC risk in patients with HCV, evaluate the effects of two single nucleotide polymorphisms (rs2149356, rs1927914) of TLR4 gene on liver fibrosis in chronic hepatitis C patients and determine the frequency of alleles of TLR4 gene in HCV patient and HCC patients as compared to healthy control. This study was carried out during the period from September 2018 to December 2020. Patients were randomly selected from those admitted to National liver institute, Menoufia University. This study included 100 HCC patients, 100 chronic HCV patients (CHC) and 100 apparently healthy volunteers as a control group. All participants were subjected to: 1. History taking. 2. Complete clinical examination. 3. Laboratory investigations; (Complete blood count, Prothrombin concentration, INR, Liver function tests and Hepatitis markers; hepatitis C virus antibody (anti HCV), Hepatitis B surface antigen (HBsAg). 4. Measurement of serum Alpha fetoprotein (AFP) level by two-step sandwich solid phase enzyme immunoassay. 5. Detection of HCV RNA by quantitative Real Time PCR. 6. Detection of TLR4 single-nucleotide polymorphisms (rs2149356, rs1927914) by PCR RFLP. The results of the present study revealed that: This cohort study included 200 patients chronically infected with HCV and 100 healthy controls. They were categorized into three groups. Demographic analysis of the studied subjects revealed no statistically significant difference between the three groups. |